These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 34043007)

  • 1. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
    Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
    Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AAV5-miHTT-mediated huntingtin lowering improves brain health in a Huntington's disease mouse model.
    Thomson SB; Stam A; Brouwers C; Fodale V; Bresciani A; Vermeulen M; Mostafavi S; Petkau TL; Hill A; Yung A; Russell-Schulz B; Kozlowski P; MacKay A; Ma D; Beg MF; Evers MM; Vallès A; Leavitt BR
    Brain; 2023 Jun; 146(6):2298-2315. PubMed ID: 36508327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
    Caron NS; Byrne LM; Lemarié FL; Bone JN; Aly AE; Ko S; Anderson C; Casal LL; Hill AM; Hawellek DJ; McColgan P; Wild EJ; Leavitt BR; Hayden MR
    Transl Neurodegener; 2024 Oct; 13(1):50. PubMed ID: 39380076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
    Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
    Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease.
    Morena E; Romano C; Marconi M; Diamant S; Buscarinu MC; Bellucci G; Romano S; Scarabino D; Salvetti M; Ristori G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease.
    Niccolini F; Haider S; Reis Marques T; Muhlert N; Tziortzi AC; Searle GE; Natesan S; Piccini P; Kapur S; Rabiner EA; Gunn RN; Tabrizi SJ; Politis M
    Brain; 2015 Oct; 138(Pt 10):3016-29. PubMed ID: 26198591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
    Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
    Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hybrid 2-[18F] FDG PET/MRI in premanifest Huntington's disease gene-expansion carriers: The significance of partial volume correction.
    Hellem MNN; Vinther-Jensen T; Anderberg L; Budtz-Jørgensen E; Hjermind LE; Larsen VA; Nielsen JE; Law I
    PLoS One; 2021; 16(6):e0252683. PubMed ID: 34115782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VGLUT3 Deletion Rescues Motor Deficits and Neuronal Loss in the zQ175 Mouse Model of Huntington's Disease.
    Ibrahim KS; El Mestikawy S; Abd-Elrahman KS; Ferguson SSG
    J Neurosci; 2023 Jun; 43(23):4365-4377. PubMed ID: 37055181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative Electroencephalographic Analysis Provides an Early-Stage Indicator of Disease Onset and Progression in the zQ175 Knock-In Mouse Model of Huntington's Disease.
    Fisher SP; Schwartz MD; Wurts-Black S; Thomas AM; Chen TM; Miller MA; Palmerston JB; Kilduff TS; Morairty SR
    Sleep; 2016 Feb; 39(2):379-91. PubMed ID: 26446107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease.
    Yang S; Chang R; Yang H; Zhao T; Hong Y; Kong HE; Sun X; Qin Z; Jin P; Li S; Li XJ
    J Clin Invest; 2017 Jun; 127(7):2719-2724. PubMed ID: 28628038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
    Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
    J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models.
    Morelli KH; Wu Q; Gosztyla ML; Liu H; Yao M; Zhang C; Chen J; Marina RJ; Lee K; Jones KL; Huang MY; Li A; Smith-Geater C; Thompson LM; Duan W; Yeo GW
    Nat Neurosci; 2023 Jan; 26(1):27-38. PubMed ID: 36510111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease.
    Kacher R; Lamazière A; Heck N; Kappes V; Mounier C; Despres G; Dembitskaya Y; Perrin E; Christaller W; Sasidharan Nair S; Messent V; Cartier N; Vanhoutte P; Venance L; Saudou F; Néri C; Caboche J; Betuing S
    Brain; 2019 Aug; 142(8):2432-2450. PubMed ID: 31286142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meso scale discovery-based assays for the detection of aggregated huntingtin.
    Reindl W; Baldo B; Schulz J; Janack I; Lindner I; Kleinschmidt M; Sedaghat Y; Thiede C; Tillack K; Schmidt C; Cardaun I; Schwagarus T; Herrmann F; Hotze M; Osborne GF; Herrmann S; Weiss A; Zerbinatti C; Bates GP; Bard J; Munoz-Sanjuan I; Macdonald D
    PLoS One; 2019; 14(3):e0213521. PubMed ID: 30913220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of HTT inclusion size, location, and timing in the zQ175 mouse model of Huntington's disease: an in vivo high-content imaging study.
    Carty N; Berson N; Tillack K; Thiede C; Scholz D; Kottig K; Sedaghat Y; Gabrysiak C; Yohrling G; von der Kammer H; Ebneth A; Mack V; Munoz-Sanjuan I; Kwak S
    PLoS One; 2015; 10(4):e0123527. PubMed ID: 25859666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramipexole reduces soluble mutant huntingtin and protects striatal neurons through dopamine D3 receptors in a genetic model of Huntington's disease.
    Luis-Ravelo D; Estévez-Silva H; Barroso-Chinea P; Afonso-Oramas D; Salas-Hernández J; Rodríguez-Núñez J; Acevedo-Arozena A; Marcellino D; González-Hernández T
    Exp Neurol; 2018 Jan; 299(Pt A):137-147. PubMed ID: 29056363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.